|
|
|
|
|
|
by svnt
1287 days ago
|
|
|
It never had before, because a commercial mRNA vaccine had never been the right trade off of immunity vs development time. Until COVID-19 there had not been a pandemic we needed to address with a vaccine since mRNA vaccination tech became widespread several decades ago. If we had enough time to develop a vaccine, why sell a new one that doesn’t work as well as the old kind? |
|
|